Evidence map›Paper›PMID 29254194›Full record

ArticleOncotarget2017

Cardioprotective properties of N-terminal galanin fragment (2-15) in experimental ischemia/reperfusion injury.

Oleg Pisarenko, Andrei Timotin, Maria Sidorova, Irina Studneva, Valentin Shulzhenko, Marina Palkeeva, Larisa Serebryakova, Aleksander Molokoedov, Oksana Veselova, Mathieu Cinato and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Oleg Pisarenko *Russian Cardiology Research and Production Complex, Moscow, Russian Federation.
Andrei Timotin *National Institute of Health and Medical Research (INSERM) U1048, Toulouse, France.
Maria SidorovaRussian Cardiology Research and Production Complex, Moscow, Russian Federation.
Irina StudnevaRussian Cardiology Research and Production Complex, Moscow, Russian Federation.
Valentin ShulzhenkoRussian Cardiology Research and Production Complex, Moscow, Russian Federation.
Marina PalkeevaRussian Cardiology Research and Production Complex, Moscow, Russian Federation.
Larisa SerebryakovaRussian Cardiology Research and Production Complex, Moscow, Russian Federation.
Aleksander MolokoedovRussian Cardiology Research and Production Complex, Moscow, Russian Federation.
Oksana VeselovaRussian Cardiology Research and Production Complex, Moscow, Russian Federation.
Mathieu CinatoNational Institute of Health and Medical Research (INSERM) U1048, Toulouse, France.
Frederic BoalNational Institute of Health and Medical Research (INSERM) U1048, Toulouse, France.
Helene TronchereNational Institute of Health and Medical Research (INSERM) U1048, Toulouse, France.
Oksana Kunduzova *National Institute of Health and Medical Research (INSERM) U1048, Toulouse, France.
Institute of Experimental Cardiology · RUInserm · FRUniversité Toulouse III - Paul Sabatier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeGalanin is an endogenous peptide involved in diverse physiological functions in the central nervous system including central cardiovascular regulation. The present study was designed to evaluate the potential effects of the short N-terminal galanin fragment 2-15 (G) on cardiac ischemia/reperfusion (I/R) injury. EXPERIMENTAL APPROACH: Peptide G was synthesized by the automatic solid phase method and identified by 1H-NMR spectroscopy and mass spectrometry. Experiments were performed on cultured rat cardiomyoblast (H9C2) cells, isolated perfused working rat hearts and anaesthetized open-chest rats. KEY

resultsCell viability increased significantly after treatment with 10 and 50 nM of G peptide. In hypoxia and reoxygenation conditions, exposure of H9C2 cells to G peptide decreased cell apoptosis and mitochondrial reactive oxygen species (ROS) production. Postischemic infusion of G peptide reduced cell membrane damage and improved functional recovery in isolated hearts during reperfusion. These effects were accompanied by enhanced restoration of myocardial metabolic state. Treatment with G peptide at the onset of reperfusion induced minor changes in hemodynamic variables but significantly reduced infarct size and plasma levels of necrosis markers. CONCLUSION AND IMPLICATIONS: These findings suggest that G peptide is effective in mitigating cardiac I/R injury, thereby providing a rationale for promising tool for the treatment of cardiovascular diseases.

Indexed as

apoptosiscardiac injuryenergy metabolismgalanin (2-15)oxidative stress

Identifiers

PMID29254194
PMCPMC5731904
OpenAlexW2762110189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.